Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTR5A | P47898 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12533540 | 0.84 | LMNA (0.38) | MAPKAPK2NOS3NOS1NOS2TSHR | |
| SCHEMBL10442292 | 0.84 | TSHR (0.46) | NOS3NOS1NOS2TSHRCYP3A4 | |
| SCHEMBL6197292 | 0.78 | TSHR (0.33) | TSHRHTR5A | |
| SCHEMBL8889457 | 0.78 | TAAR1 (0.44) | TSHRHTR5ATAAR1 | |
| SCHEMBL2177894 | 0.78 | HTR2C (0.40) | TSHRHTR5A | |
| SCHEMBL1389255 | 0.78 | AR (0.41) | MAPKAPK2TSHRHTR5ACYP3A4ALOX15 | |
| SCHEMBL1352303 | 0.78 | TSHR (0.33) | NOS3NOS1NOS2TSHRHTR5A | |
| SCHEMBL9008384 | 0.77 | PNMT (0.33) | TSHRHTR5A | |
| SCHEMBL319430 | 0.76 | AOC1 (0.33) | MAPKAPK2 | |
| SCHEMBL8405588 | 0.76 | CD44 (0.37) | MAPKAPK2HTR5ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390907-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-06-24 | — | — | US | disclosed |
| EP-1780211-A2 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1775295-A1 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1670794-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050153984-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2005033105-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| EP-0394440-B1 | PHENYLCARBOXYLIC ACID DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 1994-05-11 | — | — | EP | disclosed |
| US-4999378-A | Antilipemic, anticholesterol, antidiabetic, treatment of atherosclerosis and obesity | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1991-03-12 | — | — | US | disclosed |
| EP-0394440-A1 | PHENYLCARBOXYLIC ACID DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-31 | — | — | EP | disclosed |
| EP-0113922-A2 | Process for the manufacture of cationic methine dyes | BAYER AG (DE) | 1984-07-25 | — | — | EP | disclosed |
| EP-0113920-A2 | Process for the manufacture of stable solutions of cationic methine dyes, and their use in spin dyeing | BAYER AG (DE) | 1984-07-25 | — | — | EP | disclosed |
| EP-0113921-A2 | Process for the manufacture of stable solutions of cationic methine dyes | BAYER AG (DE) | 1984-07-25 | — | — | EP | disclosed |
| EP-0042556-B1 | PROCESS FOR THE MANUFACTURE OF ALKYLHYDRAZONE CATIONIC DYES AND THEIR DYESTUFF BASES | BAYER AG (DE) | 1984-02-08 | — | — | EP | disclosed |
| US-4376728-A | Process for the preparation of cationic alkylarylhydrazone dyestuffs and color bases thereof | BAYER AKTIENGESELLSCHAFT (DE) | 1983-03-15 | — | — | US | disclosed |
| EP-0042556-A2 | Process for the manufacture of alkylhydrazone cationic dyes and their dyestuff bases | BAYER AG (DE) | 1981-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153984-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | MAPKAPK2 1239/4885NOS3 801/4885NOS1 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.